Navigation Links
NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
Date:7/27/2009

EMERYVILLE, Calif., July 27 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Jesup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 9:30 am EDT. The presentation will be held at The Boca Raton Resort & Club in Boca Raton, Florida.

Dr. Najafi will provide a corporate overview and highlight NovaBay's clinical progress, business development strategy and product development candidates. His presentation will:

  • update investors on NovaBay's internal clinical programs in hospital-associated infections and respiratory infections.
  • provide information on NovaBay's recent announcements regarding the initiation of a Phase II clinical trial for the use of NovaBay's lead Aganocide(R) compound, NVC-422, for viral conjunctivitis, which is being conducted by its partner Alcon (NYSE: ACL).
  • review the recently announced partnership with Galderma, the world's leading dermatology company, for development of acne and impetigo products
  • discuss the important collaborative agreement with professors Markus Nagl, M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria, which broadens NovaBay's intellectual property estate, expands its pre-clinical pipeline and advances the development of NovaBay's Aganocide compo
    '/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
2. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
3. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
4. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
7. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
8. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
9. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
10. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
11. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... race to make solar cells cheaper and more ... on new designs that exploit nanostructures--materials engineered on ... Using nanotechnology, researchers can experiment with and control ... free electrons--properties that are important for the conversion ...
... 8 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that as permitted under,the registration ... stockholders to cease using the company,s Registration Statement ... 2008 prospectus until,further advised. This release corrects and ...
... expands SRA footprint in human health services around the ... ... overall,expansion in new markets, SRA International, Inc. (NYSE: SRX ) today,announced the ... President and Chief Financial Officer (CFO) of its new,Global Health Sector (GHS) organization. ...
Cached Biology Technology:New nanostructured thin film shows promise for efficient solar energy conversion 2New nanostructured thin film shows promise for efficient solar energy conversion 3/CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement 2SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 2SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 3
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... have uncovered a new cellular secret that may explain ... of cancers that makes treatment especially difficult. If the ... -- can be understood well enough to manipulate it, ... with metastatic cancers. , Significance of the Mayo ...
... exposure has already permanently damaged their skin cells, causing ... dark splotches and uneven skin tone over time. But ... known for treating arthritis ?can actually help stop the ... ones. , "These findings on glucosamine may impact the ...
... have taken a potentially powerful new therapy for treating ... the test tube and into animals by demonstrating it ... The research has particularly important implications for the estimated ... both nerves and blood vessels. , The therapy involves ...
Cached Biology News:Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
... can be upgraded to the GenePix Autoloader ... analyzes, and saves results for up to ... when the batch is complete. Line-by-line autofocus ... slides. GenePix Pro gives you complete flexibility ...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... your microarray data using Asuragens bioinformatics expertise. ... consultation to extensive data analysis using the ... expertise in combination with the Gene Expression ... experiments., ,Normalization and basic statistical analysis including ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: